291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC).
Saved in:
| Title: | 291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). |
|---|---|
| Authors: | Harbeck, N.1 (AUTHOR), Modi, S.2 (AUTHOR), Pusztai, L.3 (AUTHOR), Ohno, S.4 (AUTHOR), Wu, J.5 (AUTHOR), Kim, S.B.6 (AUTHOR), Fabi, A.7 (AUTHOR), Cao, X.8 (AUTHOR), Joseph, R.9 (AUTHOR), Li, R.10 (AUTHOR), Zurawski, B.11 (AUTHOR), Escrivá-de-Romaní, S.12 (AUTHOR), Chen, S.C.13 (AUTHOR), Kelly, C.14 (AUTHOR), Curigliano, G.15 (AUTHOR), Symmans, F.16 (AUTHOR), Mondal, S.17 (AUTHOR), Safdar, S.18 (AUTHOR), Herbolsheimer, P.19 (AUTHOR), Boileau, J-F.20 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS320-S321. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.720 |
